IPM Take
The NHS ctDNA rollout is powerful because it turns liquid biopsy from a promising test into a commissioned service with defined patient groups. But NHS England’s implementation letter shows the less glamorous truth of precision medicine: even a national genomic test depends on local procurement, blood collection kits, laboratory coordination and Trust-level funding mechanisms. Implementation lives or dies in these operational details.
Executive Summary
NHS England states that ctDNA testing is commissioned on the National Genomic Test Directory for patients with suspected non-small cell lung cancer, ESR1 genomic testing in breast cancer following NICE guidance on elacestrant, and PIK3CA/AKT/PTEN genomic testing in breast cancer following NICE guidance TA816 and TA1063. NHS England also notes that Trusts must now procure and fund blood collection kits locally, after central procurement ended. The national annual cost of blood collection kits is estimated at around £625,000, while NHS England cites evidence that ctDNA testing can streamline cancer diagnostics and create around £11 million in savings elsewhere in the system.
Why it matters
- Diagnostics / pathology: Need reliable blood collection, laboratory workflows, genomic interpretation and reporting standards so ctDNA results can guide timely treatment.
- Hospitals / providers: Must identify local funding and procurement routes for blood collection kits, or commissioned testing may still fail at the operational level.
- Patients / advocates: Should watch whether national commissioning translates into real access for eligible lung and breast cancer patients across all Trusts, not only prepared centres.
Before this rollout, liquid biopsy was often discussed as an emerging alternative to tissue biopsy. The shift now is that ctDNA testing has entered routine commissioning for specific cancer pathways in England.
The eligibility is defined, not universal. It includes patients with suspected non-small cell lung cancer and selected breast cancer genomic testing linked to NICE guidance. In these settings, ctDNA can help identify tumour variants through a blood sample and support faster treatment decisions, especially when tissue biopsy is difficult, delayed or insufficient. NHS England’s letter confirms that ctDNA testing is commissioned for suspected NSCLC, ESR1 testing in breast cancer, and PIK3CA/AKT/PTEN testing in breast cancer.
The implementation signal is not only scientific. NHS England states that individual Trusts are now responsible for procuring and funding blood collection kits locally. That means national commissioning still requires local operational readiness.
For IPM, this is the lesson: precision diagnostics scale only when the full pathway is funded, from test request to sample collection, laboratory processing, interpretation and treatment action. The NHS experience is important because it shows both sides of implementation: national policy can open access, but local delivery decides whether patients actually benefit.
